Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma

There is a need for effective “broad spectrum” therapies for metastatic melanoma which would be suitable for all patients. The objectives of Phase Ia/Ib studies were to evaluate the safety, pharmacokinetics, dosimetry, and antitumor activity of (188)Re-6D2, a 188-Rhenium-labeled antibody to melanin....

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, M., Lotem, M., Peretz, T., Zwas, S. T., Mizrachi, S., Liberman, Y., Chisin, R., Schachter, J., Ron, I. G., Iosilevsky, G., Kennedy, J. A., Revskaya, E., de Kater, A. W., Banaga, E., Klutzaritz, V., Friedmann, N., Galun, E., DeNardo, G. L., DeNardo, S. J., Casadevall, A., Dadachova, E., Thornton, G. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556872/
https://www.ncbi.nlm.nih.gov/pubmed/23365757
http://dx.doi.org/10.1155/2013/828329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556872/
https://www.ncbi.nlm.nih.gov/pubmed/23365757
http://dx.doi.org/10.1155/2013/828329

Ejemplares similares